Hypercholesterolemia: Clinical Trials

86 trials for Hypercholesterolemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

86 completed. 86 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 186Completed 86
Phase 28Completed 8

Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia

Trials (filtered) newest first · largest first

All 86 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia
Phase 1CompletedAJU Pharm Co., Ltd.412026-06-112026-07-10
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
AZD4954, Laroprovstat - Healthy Participants
Phase 1CompletedAstraZeneca312026-04-102026-08-04
Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets
Bempedoic acid film coated tablet, Nilemdo® Film-coated tablets - Hypercholesterolaemia
Phase 1CompletedHumanis Saglık Anonim Sirketi322025-05-212025-09-12
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults
Test Drug, Reference Drug - Hypercholesterolemia
Phase 1CompletedAJU Pharm Co., Ltd.602025-03-292025-06-12
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections - Hypercholesterolemia and Hyperlipidemia
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.492025-03-142026-07-30
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
AZD0780, Ezetimibe, Rosuvastatin - Dyslipidemia
Phase 1CompletedAstraZeneca812024-12-202025-11-10
Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets - Hypercholesterolaemia, Mixed Dyslipidaemia
Phase 1CompletedHumanis Saglık Anonim Sirketi142024-12-042025-04-11
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
Enlicitide Decanoate - Hypercholesterolaemia
Phase 1CompletedMerck Sharp & Dohme LLC332023-07-202026-09-30
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
AZD0780, Rosuvastatin - Dyslipidemia
Phase 1CompletedAstraZeneca162023-03-092025-04-27
A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
VXX-401, Placebo - Hypercholesterolemia
Phase 1CompletedAxxium Life, Inc.642023-03-072026-11-04
A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)
MK-0616 - Hypercholesterolemia
Phase 1CompletedMerck Sharp & Dohme LLC242022-10-252024-09-19
A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
Enlicitide Chloride, Placebo - Healthy, Hypercholesterolemia
Phase 1CompletedMerck Sharp & Dohme LLC562022-09-302024-10-23
A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects
BR1018-1, BR1018-2 - Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia)
Phase 1CompletedBoryung Pharmaceutical Co., Ltd362022-08-042023-05-24
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
VERVE-101 - Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Phase 1CompletedVerve Therapeutics, Inc.132022-07-052025-05-08
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
SHR-1209 - Hypercholesterolemia and Hyperlipidemia
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.1592022-05-252023-01-12
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
AZD0780, Placebo, Rosuvastatin - Dyslipidemia
Phase 1CompletedAstraZeneca1832022-05-182026-09-09
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B - Healthy Volunteers; High Cholesterol
Phase 1CompletedNovo Nordisk A/S1522022-04-122024-07-12
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
NNC0385-0434 - Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
Phase 1CompletedNovo Nordisk A/S732021-12-092023-12-26
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic
DC371739 Tablets, Placebo - Hypercholesterolemia
Phase 1CompletedGuangzhou JOYO Pharma Co., Ltd512021-04-012022-03-16
A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels
NNC0385-0434, Placebo (NNC0385-0434) - Healthy Volunteers, Hypercholesterolaemia
Phase 1CompletedNovo Nordisk A/S392019-08-202021-12-30

Showing 20 of 86. Sign in to see all of them.

Narrower conditions

Dyslipidemias (15)  ·  Hyperlipidemias (11)  ·  Hypertension (5)  ·  Cardiovascular Diseases (4)  ·  Atherosclerosis (3)  ·  Diabetes Mellitus (3)  ·  Lipid Metabolism Disorders (3)  ·  Metabolic Diseases (3)  ·  Aneurysm (2)  ·  Hypercholesterolemia, Autosomal Dominant, 3 (2)  ·  Hyperlipoproteinemia Type II (2)  ·  Hypertriglyceridemia (2)  ·  Medication Adherence (2)  ·  Obesity (2)

Broader conditions

Nutritional and Metabolic Diseases (86)  ·  Lipid Metabolism Disorders (83)  ·  Metabolic Diseases (83)  ·  Hyperlipidemias (75)  ·  Dyslipidemias (71)  ·  Vascular Diseases (7)  ·  Cardiovascular Diseases (6)  ·  Endocrine System Diseases (4)  ·  Glucose Metabolism Disorders (4)  ·  Arterial Occlusive Diseases (3)  ·  Arteriosclerosis (3)  ·  Behavior (3)  ·  Body Weight (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)

Interventions

alirocumab (10)  ·  Ezetimibe (8)  ·  Atorvastatin (6)  ·  bococizumab (6)  ·  Rosuvastatin Calcium (5)  ·  Simvastatin (4)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (3)  ·  MK-0616 (3)  ·  gemcabene (3)  ·  Drug Evaluation (2)  ·  Niacin (2)  ·  ALN-PCS (1)  ·  Adjuvants, Pharmaceutic (1)  ·  Cytokines (1)  ·  Ezetimibe, Simvastatin Drug Combination (1)

Sponsors

Sanofi (9)  ·  Pfizer (8)  ·  Merck Sharp & Dohme LLC (6)  ·  AstraZeneca (5)  ·  Jiangsu HengRui Medicine Co., Ltd. (3)  ·  NeuroBo Pharmaceuticals Inc. (3)  ·  Novartis Pharmaceuticals (3)  ·  Novo Nordisk A/S (3)  ·  Organon and Co (3)  ·  AJU Pharm Co., Ltd. (2)  ·  GlaxoSmithKline (2)  ·  Humanis Saglık Anonim Sirketi (2)  ·  National Heart, Lung, and Blood Institute (NHLBI) (2)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2)  ·  University Medicine Greifswald (2)

Countries

United States (34)  ·  China (8)  ·  United Kingdom (8)  ·  Germany (4)  ·  Australia (3)  ·  Canada (3)  ·  France (3)  ·  India (3)  ·  South Korea (3)  ·  Belgium (2)  ·  Austria (1)  ·  Brazil (1)  ·  Israel (1)  ·  Japan (1)  ·  Moldova (1)

Top investigators

Werner Siegmund, Prof (2)  ·  Adrian Di Bisceglie, MD,FACP,FAASLD (1)  ·  Brad West, ND (1)  ·  David Burger (1)

Results publications

PMID 37994400, PMID 28181260, PMID 40587053, PMID 15324521, PMID 18068514, PMID 19500003, PMID 19833861, PMID 19843338, PMID 20457158, PMID 21120461, PMID 21417623, PMID 22435370, PMID 25256660, PMID 25942458, PMID 26607938, PMID 27184170, PMID 27287699, PMID 27959715, PMID 27986651, PMID 28636184, PMID 29037448, PMID 30243503, PMID 32080823, PMID 33183320, PMID 33969434, PMID 35427476, PMID 40252193, PMID 42137960

NIH funding

2015 (1), 2019 (1)